As 2026 brings the first wave of Medicare drug price negotiations under the Inflation Reduction Act, the landscape for high-cost cardiovascular medications like Repatha (evolocumab) has shifted ...
Secondary endpoints measured the effects of Repatha compared with apheresis at week four on levels of LDL-C, non-HDL-C and total cholesterol:HDL-C ratio. About Repatha® (evolocumab) Repatha ® ...
Repatha Cardiovascular Outcomes (FOURIER) Study Design FOURIER (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a multinational Phase 3 randomized, ...
THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol ...
Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...
In this analysis of the landmark FOURIER outcomes study, 5,711 patients who experienced an MI within one to 12 months of randomization were compared to 16,609 patients with a more distant event (>12 ...
VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March 28, 2026 /PRNewswire/ -- Amgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results